Revolution Medicines Q2 net loss $98.3M; clinical updates for RMC-6236 and RMC-6291

Revolution Medicines, Inc.

2023-Q1 EPS reported -$1.65 revenue$10,838,000

Net loss of $98.3M vs $61.2M YoY; revenue from Sanofi collaboration $3.8M, down from $9.1M.
Cash, equivalents and securities $909.5M at June 30, 2023, up from $644.9M at Dec 31, 2022.
FY 2023 GAAP net loss guidance $360M–$400M; cash expected to fund operations into 2025.
Planning pivotal single-agent trials for RMC-6236; combination trial with RMC-6291 starting in early 2024.
Clinical data for RMC-6236 and RMC-6291 to be presented at ESMO and Triple Meeting in October 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Revolution Medicines, Inc. reported financial results for the quarter ended June 30, 2023.

Period: the quarter ended June 30, 2023
Result: reported results

Exact text from the filing

On August 8, 2023, Revolution Medicines, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2023.

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

Revolution Medicines, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-039773

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.